IM Cannabis (NASDAQ:IMCC – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect IM Cannabis to post earnings of ($1.03) per share for the quarter.
IM Cannabis (NASDAQ:IMCC – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.67. The business had revenue of $10.78 million during the quarter, compared to analyst estimates of $9.62 million. IM Cannabis had a negative net margin of 26.46% and a negative return on equity of 97.26%. On average, analysts expect IM Cannabis to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
IM Cannabis Stock Performance
NASDAQ:IMCC opened at $2.23 on Tuesday. The company has a market cap of $4.98 million, a P/E ratio of -0.58 and a beta of 0.45. IM Cannabis has a twelve month low of $1.13 and a twelve month high of $8.10. The company’s 50-day moving average price is $2.19 and its 200-day moving average price is $2.82. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.07.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
Featured Articles
- Five stocks we like better than IM Cannabis
- How to Use the MarketBeat Stock Screener
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- What is a Bond Market Holiday? How to Invest and Trade
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- 10 Best Airline Stocks to Buy
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.